Jun. 14 at 12:09 PM
$XERS Present time & forward looking ->
Based on ~
$390M in revenue by year-end 2026, and assuming an average annual growth rate of ~18% since 2027 through 2030, Xeris could reach ~
$760M in rev. by 2030.
I still remember calculating a 21% average growth rate 2027-2030 because I didn't yet know how strong Xeris growth would be in 2026.
For comparison, when Corcept grew rev. from
$675M in 2024 to
$761M in 2025 (12.8%), it reached a peak valuation of about
$12B during the year. In Xeris terms, that would be equivalent to ~
$70PS. If Xeris repurchases shares over time, the equivalent value could be even higher.
There are notable similarities between Xeris and Corcept: flagship endo. products (Recorlev/Korlym), specialty pharma economics, and major pipeline leverage through XP-8121/Relacorilant. Xeris also has Gvoke and Keveyis as meaningful additional assets.
Xeris represents one of those rare opportunities where ~ tenfold increase in share price by 2030 is a reasonable possibility.
